<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04572698</url>
  </required_header>
  <id_info>
    <org_study_id>LY09004/CT-CHN-302</org_study_id>
    <nct_id>NCT04572698</nct_id>
  </id_info>
  <brief_title>A Study to Compare LY09004 and Eylea in the Treatment of Wet Age-related Macular Degeneration（wAMD）</brief_title>
  <official_title>To Compare the Efficacy and Safety of Recombinant Human Vascular Endothelial Growth Factor Receptor Antibody Fusion Protein Eye Injection（LY09004） and Eylea in the Treatment of Wet Age-related Macular Degeneration（wAMD）: a Randomized, Double-blind, Parallel Controlled, Multicenter Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luye Pharma Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shan Dong Boan Biotechnology Co., Ltd(Co-sponsor)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Luye Pharma Group Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, parallel controlled, multicenter clinical trial to compare the&#xD;
      efficacy and safety of LY09004 and EYLEA in the Treatment of Wet Age-related Macular&#xD;
      Degeneration（wAMD)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, parallel controlled, multicenter clinical trial.&#xD;
&#xD;
      The primary objective is to assess the efficacy similarity of LY09004 and EYLEA in the&#xD;
      treatment of w-AMD.&#xD;
&#xD;
      The secondary objective is to assess the safety similarity of LY09004 and EYLEA in the&#xD;
      treatment of w-AMD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BCVA（best corrected visual acuity ）</measure>
    <time_frame>week 24</time_frame>
    <description>Assess the BCVA change similarity from baseline of LY09004 and EYLEA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BCVA</measure>
    <time_frame>week 4, week 8, week 12, week 16, week 20, week 28, week 32, week 36, week 40, week 44, week 48, week 52</time_frame>
    <description>Assess the BCVA change similarity from baseline of LY09004 and EYLEA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Letter</measure>
    <time_frame>week 24, week 52</time_frame>
    <description>Proportion of subjects with 5 / 10 / 15 letters more than baseline in study eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central television omentum thickness</measure>
    <time_frame>week 24, week 52</time_frame>
    <description>Changes of central television omentum thickness from baseline in study eyes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CNV(Choroidal neovascularization) leakage area</measure>
    <time_frame>week 24, week 52</time_frame>
    <description>Changes of CNV leakage area of study eye compared with baseline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>AE(adverse event)</measure>
    <time_frame>week 52</time_frame>
    <description>Number of patients with treatment related adverse events assessed by change from baseline.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">416</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>LY09004</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY09004 injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EYLEA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EYLEA injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY09004</intervention_name>
    <description>LY09004 injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.</description>
    <arm_group_label>LY09004</arm_group_label>
    <other_name>Recombinant Human Vascular Endothelial Growth Factor Receptor Antibody Fusion Protein Eye Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eylea</intervention_name>
    <description>EYLEA injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.</description>
    <arm_group_label>EYLEA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient or their legal representatives must give the written informed consent form&#xD;
             voluntarily;&#xD;
&#xD;
          2. Aged ≥ 50 years, male or female;&#xD;
&#xD;
          3. Patients confirmed diagnosis of w-AMD, currently have active lesions, which are&#xD;
             defined any of the following in the macular area: ① intraretinal fluid; ② intraretinal&#xD;
             lipid exudation; ③ subretinal fluid; ④ subretinal hemorrhage; ⑤ retinal pigment&#xD;
             epithelium detachment;&#xD;
&#xD;
          4. The total area of all types of lesions in the study eye ≤ 30mm2 (the area of 12 optic&#xD;
             discs);&#xD;
&#xD;
          5. The BCVA between 73-24 letters (including boundary values) in the study eye is&#xD;
             inclusive using the ETDRS, which is equivalent to 20/40 to 20/320 of Snellen；&#xD;
&#xD;
          6. Non-study eye use ETDRS testing to detect BCVA ≥19 letters，which is equivalent to&#xD;
             20/400 of Snellen;&#xD;
&#xD;
          7. At hte time of screening, childbearing-age (such as women who have not undergone&#xD;
             surgical sterilization or have been postmenopausal less than one year) have a negative&#xD;
             blood pregnancy test result. Childbearing-age male and female agree to take effective&#xD;
             contraceptive measures throughout the study period and for at least 3 months after&#xD;
             medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any opacity of refractive media or non-dilated pupils in the study eye interference&#xD;
             with visual acuity detection and the evaluation of anterior segment and fundus;&#xD;
&#xD;
          2. Study eye retinal hemorrhage ≥ 4 optic disc area;&#xD;
&#xD;
          3. Central fovea of the study eye affected by geographic atrophy, scars or fibrosis,&#xD;
             dense subfoveal exudation, and macula center affected by retinal pigment epithelium&#xD;
             (RPE) tear;&#xD;
&#xD;
          4. Any concurrent conditions in the study eye that affects central vision (such as&#xD;
             diabetic retinopathy, retinal vein occlusion, uveitis, vascular streaks, pathological&#xD;
             myopia, retinal detachment, macular hole, epimacular membrane, toxoplasmosis , Optic&#xD;
             nerve disease, polypoid choroidal vascular disease (PCV), etc.);&#xD;
&#xD;
          5. Any history of the following ophthalmic surgery in the study eye: vitrectomy,&#xD;
             anti-glaucoma surgery, macular transposition;&#xD;
&#xD;
          6. Any evidence of external eye surgery within 1 month or cataract surgery within 3&#xD;
             months before screening in the study eye;&#xD;
&#xD;
          7. Any the following treatment in the study eye within 3 months before screening:&#xD;
             Verteporfin photodynamic therapy (PDT), macular laser photocoagulation, transpupillary&#xD;
             thermotherapy (TTT), and other operations for the treatment of AMD;&#xD;
&#xD;
          8. Aphakia (excluding intraocular lens) or posterior lens capsule rupture (except for YAG&#xD;
             laser posterior capsulotomy after intraocular lens implantation more than 1 month from&#xD;
             screening) in the study;&#xD;
&#xD;
          9. Afferent pupil defect (APD) in the study eye;&#xD;
&#xD;
         10. Patients have received anti-VEGF(vascular endothelial growth factor ) treatment within&#xD;
             6 months before screening, such as ranibizumab, bevacizumab, conbercept, etc in any&#xD;
             eye or the whole body;&#xD;
&#xD;
         11. Use of intraocular or systemic corticosteroids within 3 months before screening, or&#xD;
             use of periocular corticosteroids within 1 month;&#xD;
&#xD;
         12. Any active intraocular or periocular infection (for example: blepharitis, infectious&#xD;
             conjunctivitis, keratitis) in either eye;&#xD;
&#xD;
         13. Any history of glaucoma;&#xD;
&#xD;
         14. Any evidence of pseudocapsular exfoliation syndrome in either eye;&#xD;
&#xD;
         15. A history of vitreous hemorrhage within 3 months before screening in either eye;&#xD;
&#xD;
         16. Any systemic drug (currently in use or may need to use) could cause lens toxicity or&#xD;
             retinal toxicity, such as desferrioxamine, chloroquine/hydroxychloroquine, tamoxifen,&#xD;
             phenothiazine, ethambutol, etc.;&#xD;
&#xD;
         17. History of allergy to the therapeutic or diagnostic drugs used in the research&#xD;
             protocol, including allergies to the test articles;&#xD;
&#xD;
         18. Diabetic subjects with diabetic retinopathy or glycosylated hemoglobin&gt; 9%;&#xD;
&#xD;
         19. Any history of surgery within 1 month before screening, and/or any currently unhealed&#xD;
             wounds, ulcers, fractures, etc.;&#xD;
&#xD;
         20. Any infectious disease requiring systemic treatment (oral, intramuscular or&#xD;
             intravenous) during screening;&#xD;
&#xD;
         21. History of a medical condition, including myocardial infarction, unstable angina&#xD;
             pectoris, coronary revascularization, cerebrovascular accidents (including TIA), other&#xD;
             thromboembolic diseases (such as thromboembolic angiitis, pulmonary embolism, deep&#xD;
             vein thrombosis, portal vein thrombosis, etc.), New York Heart Association (NYHA)&#xD;
             grade ≥ Grade II cardiac insufficiency, severely unstable ventricular arrhythmia&#xD;
             within 6 months before screening;&#xD;
&#xD;
         22. History of diffuse intravascular coagulation and obvious bleeding tendency (such as&#xD;
             hemoptysis, hematemesis, severe purpura, etc.) within 3 months before screening, or&#xD;
             use of anticoagulant and antiplatelet therapy other than aspirin/NSAIDs within 14 days&#xD;
             before screening;&#xD;
&#xD;
         23. Subjects with systemic immune diseases;&#xD;
&#xD;
         24. Poorly-controlled blood pressure (defined as: after receiving antihypertensive drugs,&#xD;
             the subject's systolic value ≥160 mmHg or diastolic value ≥100 mmHg at seat);&#xD;
&#xD;
         25. Any uncontrollable clinical disease (such as serious mental, respiratory and other&#xD;
             system diseases and malignant tumors);&#xD;
&#xD;
         26. Abnormal liver and kidney function (ALT, AST≥2.5 times the upper limit of normal;&#xD;
             total bilirubin≥1.5 times the upper limit of normal; Crea, urea/urea nitrogen≥1.2&#xD;
             times the upper limit of normal);&#xD;
&#xD;
         27. Abnormal blood coagulation function (prothrombin time&gt; upper limit of normal value 3&#xD;
             seconds or activated partial thromboplastin time&gt; upper limit of normal value 10&#xD;
             seconds);&#xD;
&#xD;
         28. Positive Hepatitis B surface antigen (HBsAg), and peripheral blood hepatitis B virus&#xD;
             deoxyribonucleic acid (HBV DNA) titer test ≥ 1 × 103 copies/mL; Under the condition of&#xD;
             positive HBsAg with peripheral blood HBV DNA titer test &lt;1x 103 copies/mL, if the&#xD;
             investigator judges that chronic hepatitis B is stable and will not increase the risk&#xD;
             of the subject, the subject is eligible for selection;&#xD;
&#xD;
         29. Positive Hepatitis C virus (HCV) antibody, Treponema pallidum antibody, and human&#xD;
             immunodeficiency virus (HIV) antibody;&#xD;
&#xD;
         30. Nursing (lactating) women;&#xD;
&#xD;
         31. Participation in clinical trials of any drug (excluding vitamins and minerals) within&#xD;
             3 months before screening;&#xD;
&#xD;
         32. Others need to be excluded according to the judgement of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Youxin Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Youxin Chen</last_name>
    <phone>8613801025972</phone>
    <email>chenyouxinpumch@163.com</email>
  </overall_contact>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 21, 2020</study_first_submitted>
  <study_first_submitted_qc>September 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2020</study_first_posted>
  <last_update_submitted>September 25, 2020</last_update_submitted>
  <last_update_submitted_qc>September 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>w-AMD</keyword>
  <keyword>LY09004</keyword>
  <keyword>EYLEA</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endothelial Growth Factors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

